Genomic and proteomic approaches to renal cell carcinoma

Journal of Nephrology

Volumn 24, Issue 2, 2011, Pages 155-164

  Zacchia, Miriam ^a   Vilasi, Annalisa ^a   Capasso, Anna ^a   Morelli, Franco ^a   de Vita, Ferdinando ^a   Capasso, Giovambattista ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Genomics; Proteomics; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; HEAT SHOCK PROTEIN 27; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; LIPOCORTIN 4; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO; RAPAMYCIN; SERUM AMYLOID ALPHA 1 PROTEIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VIMENTIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; BIOTECHNOLOGY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLEAR CELL CARCINOMA; DRUG MECHANISM; DRUG MEGADOSE; GENE; GENE FUNCTION; GENE TARGETING; GENETIC DISORDER; GENOMICS; HUMAN; KIDNEY CARCINOMA; KIDNEY CELL; KIDNEY CORTEX; KIDNEY PARENCHYMA; LOW DRUG DOSE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PROTEOMICS; SURVIVAL TIME; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT; VON HIPPEL LINDAU GENE;

CARCINOMA, RENAL CELL; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953692680     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2010.90     Document Type: Article

References (64)

1. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163-2172.
2. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res. 2004;10:6282S-6289S.
3. Banks RE, Tirukonda P, Taylor C, et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006;66:2000-2011.
4. Iliopoulos O, Eng C. Genetic and clinical aspects of familial renal neoplasms. Semin Oncol. 2000;27:138-149.
5. Nyhan MJ, O'Sullivan GC, McKenna SL. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumor suppressor. Biochem Soc Trans. 2008;36:472-478.
6. Calzada MJ, Esteban MA, Feijoo-Cuaresma M, et al. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms. Cancer Res. 2006;66:1553-1560.
7. Bisgrove BW, Yost HJ. The roles of cilia in developmental disorders and disease. Development. 2006;133:4131-4143.
8. Leung SK, Ohh M. Playing Tag with HIF: The VHL Story. J Biomed Biotechnol. 2002;2:131-135.
9. Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA. 1996;93:10589-10594.
10. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA. 1996;93:10595-10599.
11. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev. 1996;76:839-885.
12. Arany Z, Huang LE, Eckner R, et al. An essential role for p300/ CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA. 1996;93:12969-12973.
13. Lee YS, Vortmeyer AO, Lubensky IA, et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res. 2005;11:1059-1064.
14. Wenger RH. Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol. 2000;203:1253-1263.
15. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:7388-7393.
16. Rathmell WK, Wright TM, Rini BI. Molecularly targeted therapy in renal cell carcinoma. Expert Rev Anticancer Ther. 2005;5:1031-1040.
17. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001;106:148-156.
18. Rivet J, Mourah S, Murata H, et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer. 2008;112:433-442.
19. Schips L, Dalpiaz O, Lipsky K, et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol. 2007;51:168-173.
20. Sato K, Terada K, Sugiyama T, et al. Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J Exp Med. 1994;173:355-360.
21. Wang X, Hawk N, Yue P, et al. Overcoming mTOR inhibitioninduced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther. 2008;7:1952-1958.
22. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist. 2007;12:1404-1415.
23. Russell RC, Ohh M. The role of VHL in the regulation of Ecadherin: a new connection in an old pathway. Cell Cycle. 2007;6:56-59.
24. Ivanov SV, Kuzmin I, Wei MH, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA. 1998;95:12596-12601.
25. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA. 2001;98:1583-1588.
26. Rankin EB, Tomaszewski JE, Haase VH. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Res. 2006;66:2576-2583.
27. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272-1278.
28. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol. 2007;51:1502-1510.
29. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
30. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
31. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
32. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
33. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312-3318.
34. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
35. Wilkins MR, Sanchez JC, Gooley AA, et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev. 1996;13:19-50.
36. Ward DG, Cheng Y, N'Kontchou G, et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer. 2006;94:287-292.
37. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 2002;62:3609-3614.
38. Pawlik TM, Hawke DH, Liu Y, et al. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer. 2006;6:68.
39. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002;48:1296-1304.
40. Mueller J, von Eggling F, Driesch D, Schubert J, Melle C, Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol. 2005;47:885-893.
41. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res. 2004;10:8380-8385.
42. Poon TC, Sung JJ, Chow SM, et al. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology. 2006;130:1858-1864.
43. Yang SY, Xiao XY, Zhang WG, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005;5:83.
44. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882-5890.
45. Bukowski RM, Novick AC. Clinical practice guidelines: renal cell carcinoma. Cleve Clin J Med. 1997;64(Suppl 1):SI1-SI44.
46. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol. 1997;15:796-807.
47. Gitlitz BJ, Belldegrun A, Figlin RA. Immunotherapy and gene therapy. Semin Urol Oncol. 1996;14:237-243.
48. Hwa JS, Park HJ, Jung JH, et al. Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci. 2005;20:450-455.
49. Sarto C, Valsecchi C, Magni F, et al. Expression of heat shock protein 27 in human renal cell carcinoma. Proteomics. 2004;4:2252-2260.
50. Sarto C, Frutiger S, Cappellano F, et al. Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma. Electrophoresis. 1999;20:3458-3466.
51. Unwin RD, Craven RA, Harnden P, et al. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics. 2003;3:1620-1632.
52. Zimmermann U, Balabanov S, Giebel J, et al. Increased expression and altered location of annexin IV in renal clear cell carcinoma: a possible role in tumor dissemination. Cancer Lett. 2004;209:111-118.
53. Unwin RD, Harnden P, Pappin D, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics. 2003;3:45-55.
54. Tolson J, Bogumil R, Brunst E, et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest. 2004;84:845-856.
55. Hwa JS, Kim HJ, Goo BM, et al. The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma. Proteomics. 2006;6:1077-1084.
56. Sarto C, Marocchi A, Sanchez JC, et al. Renal cell carcinoma and normal kidney protein expression. Electrophoresis. 1997;18:599-604.
57. Perego RA, Bianchi C, Corizzato M, et al. Primary cell cultures arising from normal kidney and renal cell carcinoma retain the proteomic profile of corresponding tissues. J Proteome Res. 2005;4:1503-1510.
58. Perroud B, Lee J, Valkova N, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006;5:64.
59. Okamura N, Masuda T, Gotoh A, et al. Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics. 2008;8:3194-3203.
60. Craven RA, Stanley AJ, Hanrahan S, et al. Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics. 2006;6:2853-2864.
61. Rossi L, Martin BM, Hortin GL, et al. Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics. 2006;6:709-720.
62. Sarkissian G, Fergelot P, Lamy PJ, et al. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem. 2008;54:574-581.
63. Pieper R, Gatlin CL, McGrath AM, et al. Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics. 2004;4:1159-1174.
64. Unwin RD, Harnden P, Pappin D, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics. 2003;3:45-55.